# Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL

> **NCT01737177** · PHASE2 · COMPLETED · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 42 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bendamustine, Lenalidomide, Rituximab

## Key facts

- **NCT ID:** NCT01737177
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-31
- **Primary completion:** 2014-07
- **Final completion:** 2017-02-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01737177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01737177, "Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01737177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*